Imunochemotherapy of metastatic uveal melanoma with interferon-α2b, interleukin-2, and fotemustine: Case reports and literature review;Immunochemotherapie des metastasierenden uvea-melanoms mit interferon- α2b, interleukin-2 und fotemustin: Kasuistiken und literaturubersicht

Hautarzt

Volumn 49, Issue 10, 1998, Pages 770-773

  Terheyden, Patrick ^a   Kämpgen, Eckhart ^a   Rünger, Thomas M ^b   Bröcker, Eva Bettina ^a   Becker, Jürgen C ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Fotemustine; Interferon ; Interleukin 2; Metastases; Uveal melanoma

Indexed keywords

ALPHA2B INTERFERON; CARMUSTINE; CISPLATIN; FOTEMUSTINE; INTERLEUKIN 2; TAMOXIFEN; ANTINEOPLASTIC AGENT; NITROSOUREA DERIVATIVE; ORGANOPHOSPHORUS COMPOUND;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; HUMAN; UVEA MELANOMA; CANCER STAGING; FEMALE; FOLLOW UP; MALE; MELANOMA; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; TREATMENT OUTCOME; UVEA TUMOR;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NITROSOUREA COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 0031593716     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050823     Document Type: Article

References (23)

1. Albert DM, Niffenegger AS, Willson JKV (1992) Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol 36:429-438
2. Bedekian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, Papadopoulos N, Benjamin RS (1995) Treatment of uveal melanoma metastatic to the liver. Cancer 76:1665-1670
3. Chang J, Atkinson H, A'Hern R, Lorentzos A, Gore ME (1994) A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Eur J Cancer 30A:2093-2095
4. Cutler SJ, Young JL, Conelly RR (1975) Third national cancer survey: incidence data. Natl Cancer Inst Monogr 41:1-454
5. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP (1992) A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 110:245-250
6. Dorval T, Fridman WH, Mathiot C, Pouillart P (1992) Interleukin-2 therapy for metastatic uveal melanoma. Eur J Cancer 28A:2087 [letter]
7. Fety R, Lucas C, Solere P, Cour V, Vignoud J (1992) Hepatic intraarterial infusion of fotemustine: pharmacokinetics. Cancer Chemother Pharmacol 31:118-122
8. Fuchs U, Kivela T, Summanen P, Immonen I, Tarkkanen A (1992) An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma. Am J Pathol 141:169-181
9. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98:383-390
10. Jaquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbat P, Bonerandi JJ (1990) Final report of the french multicentric phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66:1873-1878
11. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Höffken K, Seeber S (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer 72:2219-2223
12. Khayat D, Cour V, Bizarri JP, Aigner K, Borel C, Cohen-Alloro G, Weil M, Auclerc G, Buthiau D, Bousquet JC (1991) Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II study. Am J Clin Oncol 14:400-404
13. Leyvraz S, Spartaro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15:2589-2595
14. Mavligit GM, Charnsangavej C, Carrasco CH, Patt YZ, Benjamin RS, Wallace S (1988) Regression of ocular melanoma metastatic to the liver after hepatic chemoembolisation with cisplatin and polyvinyl sponge. JAMA 260:974-976
15. Mooy CM, de Jong PTVM (1996) Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 41:215-228
16. Mulcahy KA, Rimoldi D, Brasseur F, Rodgers S, Lienard D, Marchand M, Rennie IG, Murray AK, Mclntyre CA, Platts KE, Leyvraz S, Boon T Rees RC (1996) Infrequent expression of the MAGE gene family in uveal melanomas. Int J Cancer 66:738-742
17. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, di Filippo F, Giannarelli D, Temponi M, Ferrone S (1997) Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 57:1554-1560
18. Nathan FE, Berd D, Sato T, Shield JA, Shields CL, de Potter P, Mastrangelo MJ (1997) BOLD+interferon in the treatment of uveal melanoma: first report of active systemic therapy. J Clin Oncol 16:201-208
19. Pach JM, Robertson DM (1986) Metastasis from untreated uveal melanoma. Arch Ophthalmol 104:1624-1625
20. Rajpal S, Moore R, Karakousis CP (1983) Survival in metastatic ocular melanoma. Cancer 52:334-336
21. Ruiz RS (1985) Malignant melanoma of the choroid and ciliary body. Cancer Bull 37:6-12
22. Shields JA (1993) Management of uveal melanoma. A continuing dilemma. Cancer 72:2067-2068
23. Verbik DJ, Murray TG, Tran JM, Ksander BR (1997) Melanomas that develop within the eye inhibit lymphocyte proliferation. Int J Cancer 73:470-478